. Author manuscript; available in PMC: 2015 Apr 30.

Published in final edited form as: Sci Transl Med. 2015 Feb 25;7(276):276ra26. doi: 10.1126/scitranslmed.3010101

Table 3.

Pharmacokinetics of HPβCD after intracisternal (IC) or intravenous (IV) administration in normal control cats.

Analyte	Route of Administration	Dose	Matrix	C₀ (μg/mL)	AUC_0-∞ (μg·h/mL)	AUC_0–24h (μg;·h/mL)	t_½ (h)	CL/F (mL/h·kg)	Vd_ss (mL/kg)
HPβCD (Sigma)	IC	120 mg	CSF	11645	28614		.7–2.6
HPβCD (Kleptose)	IC	30 mg	CSF	15400	23300	23100	3.22	1.29	4.14
HPβCD (Kleptose)	IV	1000 mg/kg	CSF	13.1	NC	346	NC^*	NC^*	NC^*
HPβCD (Kleptose)	IV	1000 mg/kg	Plasma	3760	4660	6770	1.11	215	336

Not calculated due to below detectable concentrations for some samples